News

Why today’s models will always be interim ones-andhow the consumerization of healthcare will drive change.

Expert offers specific actions for managed care execs to take

In today’s increasingly consumer-driven environment, personalization is not only expected, but a demanded part of the user experience.

FDA approved once-daily Yosprala (Aralez), a fixed-dose combination of aspirin, an anti-platelet agent and omeprazole, a proton pump inhibitor (PPI), for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers.Here are the top 5 facts to know about Yosprala.

Even though an FDA panel recommended against approving a new drug to treat Duchenne muscular dystrophy in April, the agency granted accelerated approval to eteplirsen injection (Exondys 51, Sarepta Therapeutics) in mid-September.

Industry leaders share who they call when they need advice.

A new study shows that many adults with depression don’t receive treatment, whereas others receive treatments that do not match their level of illness severity.

Two fertility experts detail the pros and cons of a fertility benefit plan.

Nationwide class action suit spurs new coverage decision for hepatitis C medications.

A new database helps payers understand which genetic tests are available, which genes they test for, and which tests would be appropriate to use to inform patient management.

Patient engagement is central to improving health outcomes and reducing the cost of care. Yet, there continues to be a huge disconnect between patients, payers, and physicians.

Here are five ways to use big data and predictive analytics to get insights about members and create a personalized member experience.

A new study highlights why vaccination costs should be a top consideration when evaluating benefit offerings.

Here’s how you can take advantage of this breathing room.

Market forces are converging, giving momentum to provider-sponsored health plans.

Study shows that an integrated pharmacy approach with community mental health centers produces higher adherence rates and lower overall healthcare costs.

As external pressures such as government regulations continue to mount and alter the approach to deal making in the healthcare sector, there are five things health services executives should watch.

Where do the capabilities of healthcare technology end and the need for the human hand begin to deliver top value for managed care executives?

Several recent studies explore how weight loss surgery impacts diabetes patient care.

Early planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.

FDA’s approval of a new biosimilar-the third FDA-approved biosimilar-stands to save the US healthcare system millions of dollars.

Technology in pharmacy is leading to improved safety, accountability, and efficiency.

The proposed HHS Notice of Benefit and Payment Parameters for 2018 indicates CMS is focusing on refining the risk adjustment model to better compensate plans.

The opioid crisis in the U.S. is a multidimensional problem requiring a multistakeholder solution.

This model, touted as “next-generation,” combines retail and specialty and mail services and PBM along with immediate care clinics.

CMS’ Quality Payment Program (QPP) introduced in the Medicare Access and CHIP Reauthorization Act (MACRA) has created a seismic effect across provider organizations.

Managed Healthcare Executive asked industry experts to share their favorite mobile apps for healthcare. Here’s 13 of their top picks.

Managed Healthcare Executive recently invited a panel of experts representing different sectors of the healthcare industry to explore specialty pharmaceutical challenges and identify potential solutions.

Learning how to appreciate the value of experiences is key for these execs, who share their biggest career mistake was and how they learned from it.

Despite offering a generic version of its EpiPen, Mylan has been unable to curb the backlash that began in late August over the cost of its epinephrine injection.